

## SUMMARY OF FINAL EVALUATIONS

Agent	Degree of evidence of carcinogenicity		Overall evaluation of carcinogenicity to humans
	Human	Animal	
Oral contraceptives, combined	S <sup>a</sup>		1
Hormonal contraceptives, progestogen-only	I		2B
Post-menopausal oestrogen therapy	S		1
Post-menopausal oestrogen-progestogen therapy	L		2B
<i>Oestrogens</i>			
Conjugated equine oestrogens		L	
d-Equilenin		I	
Equilin		L	
Ethinylestradiol		S	
Mestranol		S	
Oestradiol		S	
Oestriol		L	
Oestrone		S	
<i>Progestogens</i>			
Chlormadinone acetate		L	
Cyproterone acetate		L	
Ethynodiol diacetate		L	
Levonorgestrel		I	
Lynoestrenol		S	
Medroxyprogesterone acetate		S	
Megestrol acetate		L	
Norethisterone		L	
Norethisterone acetate		L	
Norethynodrel		S	
Norgestrel		I	
<i>Combinations</i>			
Conjugated equine oestrogens (O) + progestogen (P)		I	
Ethinylestradiol (O) + chlormadinone acetate (P)		L	
Ethynodiol diacetate (O) + ethynodiol diacetate (P)		S	
Ethinylestradiol (O) + megestrol acetate (P)		L	
Ethyloestradiol (O) + norethisterone (P)		L	
Ethyloestradiol (O) + norgestrel (P)		L	
Mestranol (O) + chlormadinone acetate (P)		L	
Mestranol (O) + ethynodiol diacetate (P)		L	
Mestranol (O) + lynoestrenol (P)		L	
Mestranol (O) + norethisterone (P)		L	
Mestranol (O) + norethynodrel (P)		S	

S, sufficient evidence; I, inadequate evidence; L, limited evidence; group 1, carcinogenic to humans; group 2B, possibly carcinogenic to humans; for definitions of criteria for degrees of evidence and groups, see preamble, pp. 23-27.

O, oestrogen; P, progestogen

<sup>a</sup> Hepatocellular carcinomas, high-dose preparations